NCT02621151 2025-10-07
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
NYU Langone Health
Phase 2 Active not recruiting
Clinical Trials
1 trialsActive not recruiting × Interventional × Muscle-invasive Urothelial Cancer of the Bladder × Clear all